Kp. Dieckmann et V. Loy, PREVALENCE OF CONTRALATERAL TESTICULAR INTRAEPITHELIAL NEOPLASIA IN PATIENTS WITH TESTICULAR GERM-CELL NEOPLASMS, Journal of clinical oncology, 14(12), 1996, pp. 3126-3132
Purpose: Testicular intraepithelial neoplasia ([TIN], so-called carcin
oma in situ of the testis) is hypothesized to be the precursor of test
icular germ cell neoplasms. According to previous studies, it can be d
etected by testicular biopsy. Since patients with a unilateral testicu
lar tumor are at high risk of a second testicular tumor, it seemed fea
sible to examine the prevalence of contralateral TIN in patients with
testicular germ cell cancer and correlate it with the known prevalence
of bilateral testicular tumors, The aim was to provide more evidence
for the role of TIN as the preinvasive stage of testicular cancer. Pat
ients and Methods: Nineteen hundred fifty-four consecutive patients wi
th a unilateral testicular germ cell tumor underwent contralateral bio
psy. All specimens were examined immunohistologically. Results: TIN wa
s observed in 4.9% (95% confidence interval [CI], 3.95% to 5.91%). Tes
ticular atrophy and a history of undescended testis were more frequent
ly observed in patients with contralateral TIN, but only atrophy was s
hown to be independently associated by multivariate analysis. Patients
with testicular atrophy have a 4.3-fold increased risk of having cont
ralateral TIN. Sixty-four percent of TIN cases were found in normal te
stes. Patients with TIN were significantly younger than those without
(P < .0017). Three patients developed a second testicular tumor despit
e a negative biopsy for TIN. Conclusion: The prevalence of contralater
al TIN corresponds well to the known prevalence of bilateral testicula
r tumors. Testicular atrophy is a strong indicator for the presence of
TIN, but approximately 60% of TIN cases occur without atrophy. The pr
esent data are in accordance with the theory that TIN is an early step
in the histogenesis of testicular germ cell neoplasms. (C) 1996 by Am
erican Society of Clinical Oncology.